Table II.

Significant SNPs associated with overall survival (N = 598)

Gene	SNP	Modela	HRb	P	BootstrapcP < 0.05
BMP2	rs235756	rec	1.45 (1.11–1.90)	0.006	100
SMAD3	rs4776342	add	1.25 (1.06–1.47)	0.009	96
SMAD3	rs6494633	rec	0.73 (0.56–0.93)	0.01	99
SMAD3	rs12102171	dom	1.32 (1.07–1.63)	0.01	95
SMAD6	rs12913975	dom	1.29 (1.05–1.59)	0.01	93
SMAD7	rs7227023	dom	0.70 (0.53–0.92)	0.01	100
SMAD9	rs7333607	rec	0.52 (0.31–0.87)	0.01	96
TGFB1	rs4803455	dom	1.31 (1.04–1.65)	0.02	87
ACVR2A	rs1424954	rec	0.63 (0.43–0.93)	0.02	81
SMAD4	rs948588	dom	0.70 (0.52–0.95)	0.02	61
SMAD6	rs12906898	add	1.19 (1.03–1.38)	0.02	33
BMP1	rs3857979	rec	0.77 (0.60–0.97)	0.03	54
INHBC	rs4760259	rec	0.68 (0.48–0.96)	0.03	85
SMAD1	rs11939979	dom	0.77 (0.61–0.97)	0.03	55
SMAD1	rs11724777	rec	1.37 (1.04–1.81)	0.03	85
SMAD4	rs12456284	dom	1.25 (1.02–1.54)	0.03	61
BMP1	rs7838961	dom	1.28 (1.01–1.62)	0.04	26
BMP4	rs8014071	add	1.17 (1.00–1.36)	0.04	22
BMP4	rs17563	add	1.15 (1.01–1.32)	0.04	11
SMAD3	rs11632964	add	0.86 (0.75–0.99)	0.04	40
SMAD3	rs750766	rec	1.29 (1.01–1.64)	0.04	41
SMAD8	rs511674	dom	0.64 (0.43–0.97)	0.04	16

Note. ^a Genetic model of inheritance: dom, dominant model; rec, recessive model; add, additive model.

^bAdjusted for age, sex, ethnicity, smoking status, clinical stage, PS, chemotherapy regimen and therapy modality.

^cBootstrap analysis was performed using 100 replicates to determine statistical support.